Τίτλος:
Circulating chemoattractants RANTES, negatively related to endogenous
androgens, and MCP-1 are differentially suppressed by hormone therapy
and raloxifene
Περίληψη:
Background: The cardinal role of chronic inflammation in the development
of atherosclerosis is increasingly being recognized. Estrogens may
prevent the evolution of atherosclerosis by suppressing immune response.
Furthermore, the conflicting reports on the cardiovascular effects of
hormone therapy between observational and clinical trials have triggered
interest on the effect of alternative therapies on the cardiovascular
system.
Objective: The aim of this study was to assess the effect of estrogen,
estrogen-progestin, tibolone and raloxifene therapy on circulating
markers of chemotaxis in healthy postmenopausal women.
Methods: Eighty-eight postmenopausal women aged 44-62 years were
randomly allocated to daily: (1) conjugated equine estrogens 0.625 mg
(CEE), (2) 17 beta-estradiol I mg plus norethisterone acetate 0.5 mg
(E-2/NETA), (3) tibolone 2.5 mg, (4) raloxifene HCl 60 mg or (5) no
treatment. Serum monocyte chemoattractant protein- I (MCP-1) and
regulated upon activation, normal T-cell expressed and secreted (RANTES)
were measured at baseline and at 3 months.
Results: Endogenous testosterone and free androgen index (FAI)
correlated negatively, while SHBG correlated positively with serum
RANTES (testosterone: r=-0.27,p=0.033;FA1: r=-0A3,p=0.004: SHBG:
r=0.34,p=0.026). Serum MCP-1 decreased significantly in the CEE group
(baseline 125.3 +/- 51 pg/ml, 3 months 84.5 +/- 36.1 pg/ml, p = 0.043),
while no difference was detected between baseline and post-treatment
levels in the other groups. Furthermore, a significant decrease in serum
RANTES was observed at the end of 3 months only in the E2/NETA and the
raloxifene group (E2/NETA baseline 8690.6 +/- 3880.0 pg/ml, 3 months
6894.0 +/- 1720.0 pg/ml, p = 0.007; raloxifene baseline 9042.4 +/-
3765.6 pg/mI, 3 months 6718.1 +/- 2366.2 pg/ml, p = 0.011).
Conclusion: Endogenous androgens may suppress chemotactic response.
Postmenopausal hormone therapy and raloxifene may inhibit the expression
of chemoattractant molecules and thus attenuate inflammation. The
relevance of these findings in terms of clinically established
caridoprotection remains to be clarified. (c) 2006 Elsevier Ireland Ltd.
All rights reserved.
Συγγραφείς:
Christodoulakos, George E.
Lambrinoudaki, Irene V.
Economou,
Emmanuel V.
Papadias, Constantinos
Vitoratos, Nikolaos and
Panoulis, Constantinos P.
Kouskouni, Evangelia E.
Vlachou, Sofia
A.
Creatsas, George C.
